Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Fagron in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $17.71.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Fagron.
Fagron NV, a pharmaceutical compounding company, provides personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients. It prepares personalized ready-to-use medication in its sterile and non-sterile compounding facilities. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it offers pharmaceutical raw materials, equipment, and supplies that pharmacists need to prepare medication in the pharmacy. Further, the company develops, manufactures, and supplies mixing equipment that pharmacists can use for the compounding of semi-solid dermatological formulations. It has operations in Europe, the Americas, the Middle East, and Africa, as well as Asia and the Pacific. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.